PEMIVIBART (pem iv i bart) reduces the risk of COVID-19. It does not treat COVID-19. It is still possible to get COVID-19 after receiving this medication, but the symptoms may be less severe or not last as long. It works by helping people with a weak immune system fight off a future infection. It is a monoclonal antibody. The FDA has allowed the emergency use of this medication.


PEMGARDA (EUA) Information

En Español En Español

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.